India's first indigenous dengue vaccine, DengiAll, has crossed 70% enrolment in its Phase III trial, involving over 10,000 participants across 20 sites. Developed by Panacea Biotec under a NIH license, the tetravalent, single-dose vaccine targets all four dengue virus strains and has shown promising safety results. Completion is expected by October 2025.